Please assess the completion status of the following clinical trial:

Trial Title: Remifemin Preventing the Climacteric Symptoms in Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. provision of informed consent~2. clinical stage I\~IIIC~3. histologically proven invasive breast cancer~4. women defined as premenopausal according to NCCN guideline~5. plan to accept the LHRH-a as endocrine treatment or ovarian function protection~Exclusion Criteria:~1. clinical evidence of metastatic disease~2. bilateral oophorectomy~3. patients who, for whatever reason (e.g., confusion, infirmity, alcoholism), are unlikely to comply with trial requirements~4. patients who accepted anti-cancer treatment before~5. previous hormonal therapy as adjuvant treatment for non-cancer disease~6. patients unwilling to stop taking any drug known to affect sex hormonal status, or in whom it would be inappropriate to stop previous history of invasive malignancy within the last 5 years, other than squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix, adequately cone biopsied~7. treatment with a non-approved or experimental drug during 1 month before entry into the study~8. history of bleeding diathesis (i.e., Disseminated intravascular coagulation, clotting factor deficiency), or long term anticoagulant therapy (other than antiplatelet therapy and low dose warfarin)~9. leukopenia and/or thrombocytopenia~10. history of ocular fundus diseases~11. history of thromboembolic diseases~12. history of osteoporotic fractures

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Remifemin intervention (Type: EXPERIMENTAL): Using Remifemin during LHRH-a treatment in breast cancer
- Control (Type: NO_INTERVENTION): No intervention during LHRH-a treatment in breast cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).